文献速递贫血与红细胞疾病

羧基麦芽糖铁相关低磷血症的系统综述

Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review.
PubMed 文献 · Am J Hematol · 2025-02-11

本文系统综述了FDA不良事件报告、病例报告、观察性数据库、临床试验、荟萃分析及FDA批准的药品标签中羧基麦芽糖铁(FCM)相关低磷血症(HPP)的资料。临床试验显示FCM相关HPP发生率为50%至92%,而其他静脉铁剂为2%至8%。作者认为需要更有力的推荐来预防骨软化和骨折等不良结局,并建议监测血清磷水平。

要点

  • FCM相关HPP的常见临床表现为全身乏力、疲劳、骨痛、肌痛、骨软化和骨折。
  • 临床试验中FCM相关HPP发生率为50%至92%,其他静脉铁剂为2%至8%。
  • 作者建议FCM药品标签应建议所有患者在首次剂量前和后续剂量前监测血清磷水平。

核心结论

  • 作者认为,尽管FDA批准的FCM处方标签已于2023年更新,但仍需要更有力的关于FCM相关HPP的推荐,以预防骨软化和骨折等不良结局。
  • 作者建议,为患者安全,FCM标签应建议所有患者在开始首次剂量前和后续剂量前监测血清磷水平。
  • 作者认为,鉴于FDA批准的FCM标签与本文综述数据之间的差异,必须对临床医生进行关于FCM相关HPP、治疗HPP病例的困难以及应考虑使用HPP发生率较低的其他静脉铁剂的教育。

研究设计与样本

  • 本系统综述检索了报告至FDA的HPP相关不良事件、病例报告、病例系列、观察性数据库、临床试验、荟萃分析和FDA批准的标签。

主要发现

  • FCM相关HPP最常见的临床表现为全身乏力、疲劳、骨痛、肌痛、骨软化和骨折。
  • 比较FCM与其他静脉铁剂的临床试验发现,FCM相关HPP发生率为50%至92%,而其他静脉铁剂为2%至8%。
  • 荟萃分析和系统综述证实了上述数字。
  • FDA批准的FCM标签未包含病例报告、病例系列、观察性数据库、随机试验和荟萃分析中可获得的ADR信息的细节。

关键数值与推荐

  • 临床试验中FCM相关HPP发生率为50%至92%,其他静脉铁剂为2%至8%。

临床怎么用

  • 作者建议,为患者安全,FCM标签应建议所有患者在开始首次剂量前和后续剂量前监测血清磷水平。
  • 作者认为,临床医生必须接受关于FCM相关HPP的教育,并应考虑使用HPP发生率较低的其他静脉铁剂。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2015, ferric carboxymaltose (FCM), an intravenous (IV) iron formulation used for treating iron deficiency anemia (IDA), has been associated with an increasing number of reported hypophosphatemia (HPP) cases. Information on HPP clinical manifestations and incidence has not been reviewed. METHODS: We reviewed HPP-associated adverse events reported to the FDA, case reports, case series, observational databases, clinical trials, meta-analyses, and FDA-approved labels. Our analysis found that FCM-associated HPP is a clinically important adverse drug reaction (ADR). The most common clinical manifestations are general weakness, fatigue, bone pain, muscle pain, osteomalacia, and fractures. Information on rates of FCM-associated HPP was from a review of clinical trials, observational databases, systematic reviews, and meta-analyses. RESULTS: Clinical trials comparing FCM with other IV iron preparations identified FCM-associated HPP rates between 50% and 92% versus 2% and 8% with other IV iron formulations. Meta-analyses and systematic reviews confirmed these numbers. FDA-approved FCM labels do not include details of available ADR information in case reports, case series, observational databases, randomized trials, and meta-analyses. CONCLUSION: We conclude that although the FDA-approved FCM Prescribing Label was updated in 2023, more robust recommendations on FCM-associated HPP are needed to prevent negative outcomes including osteomalacia and fractures. For patient safety, FCM label should advise monitoring serum phosphate levels prior to initiating first doses and before subsequent doses for all patients. Given differences between the FDA-approved FCM label and data reviewed herein, clinicians must be educated about FCM-associated HPP, difficulties treating HPP cases, and should consider administering other IV iron formulations that have lower rates of HPP.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Magagnoli J, Knopf K, Hrushesky WJ, et al. Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review. Am J Hematol. 2025. PMID: 39935027. doi:10.1002/ajh.27598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。